Content versus label claims in ephedra-containing dietary supplements

American Journal of Health-System Pharmacy

Volumn 57, Issue 10, 2000, Pages 963-969

  Gurley, Bill J ^a   Gardner, Stephanie F ^a   Hubbard, Martha A ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b NONE

Author keywords

Analysis; Canthine; Chromatography liquid; Concentration; Content uniformity; Control, quality; Dietary supplements; Ephedra alkaloids; Ephedra sinica; Ephedrine; I Norephedrine; Labeling; Methylephedrine; Pseudoephedrine

Indexed keywords

DIET PEP; DIET PHEN; ENERGEL; EPHEDRINE; ESCALATION; EXANDRA LEAN; EXCEL; HERBAL ECSTACY; HERBAL PF STAGE 2; HERBAL PHEN FEN; METABOLEAN; METABOLIFE; METABOMAX; METHYLEPHEDRINE; NATURAL TRIM; NOREPHEDRINE; NORPSEUDOEPHEDRINE; PSEUDOEPHEDRINE; RIPPED FUEL; TRIM FAST; TURBOTRIM PLUS; UNCLASSIFIED DRUG; UP YOUR GAS; XENADRINE;

ARTICLE; DIET SUPPLEMENTATION; DRUG DETERMINATION; DRUG INFORMATION; DRUG LABELING; EPHEDRA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL; QUALITY CONTROL;

EID: 0034658466     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/57.10.963     Document Type: Article

References (44)

1. Brevoort P. The booming U.S. botanical market: a new overview. Herbalgram. 1998; 44:33-46.
2. Zeisel SH. Regulation of "nutraceuticals." Science. 1999; 285:1853,1855.
3. Bunten W. A call for self-regulation. J Am Pharm Assoc. 1999; 39:14.
4. Hahm H, Kujawa J, Augsburger L. Comparison of melatonin products against USP's nutritional supplements standards and other criteria. J Am Pharm Assoc. 1999; 39:27-31.
5. Parasrampuria J, Schwartz K. Quality control of dehydroepiandrosterone dietary supplement products. JAMA. 1998; 280:1565. Letter.
6. Liberti LE, Der Marderosian A. Evaluation of commercial ginseng products. J Pharm Sci. 1978; 67:1487-9.
7. Cui J, Garle M, Eneroth P et al. What do commercial ginseng preparations contain? Lancet. 1994; 344:134. Letter.
8. Heptinstall S, Awang DVC, Dawson BA et al. Parthenolide content and bioactivity of feverfew (Tanacetum parthenium (L.) Schultz-Bip). Estimation of commercial and authenticated feverfew products. J Pharm Pharmacol. 1992; 44:391-5.
9. Webb G. "fX": chemically adulterated product does not contain kava. Herbalgram. 1997; 39:9.
10. Slifman NR, Obermeyer WR, Aloi BK et al. Contamination of botanical dietary supplements by Digitalis lanata. N Engl J Med. 1998; 339:806-11.
11. Ko RJ. Adulterants in Asian patent medicines. N Engl J Med. 1998; 339:847. Letter.
12. Huxtable RJ. The myth of beneficent nature: the risks of herbal preparations. Ann Intern Med. 1992; 117:165-6.
13. Ernst E. Harmless herbs? A review of the recent literature. Am J Med. 1998; 104:170-8.
14. Cupp MJ. Herbal remedies: adverse effects and drug interactions. Am Fam Physician. 1999; 59:1239-44.
15. Capwell RR. Ephedrine-induced mania from an herbal diet supplement. Am J Psychiatry. 1995; 152:647. Letter.
16. Nadir A, Agrawal S, King PD et al. Acute hepatitis associated with the use of a Chinese herbal product, ma huang. Am J Gastroenterol. 1996; 91:1436-8.
17. Adverse events associated with ephedrine-containing products - Texas, December 1993-September 1995. JAMA. 1996; 276: 1711-2.
18. Josefson D. Herbal stimulant causes U.S. deaths. Br Med J. 1996; 312:1378-9.
19. Mack RB. "All but death, can be adjusted:" ma huang (ephedrine) adversities. North Carolina Med J. 1997; 58:68-70.
20. Theoharides TC. Sudden death of a healthy college student related to ephedrine toxicity from a ma huang-containing drink. J Clin Psychopharmacol. 1997; 17:437-9. Letter.
21. Powell T, Fong FH, Turk J et al. Ma-huang strikes again: ephedrine nephrolithiasis. Am J Kidney Dis. 1998; 32:153-9.
22. Zahn KA, Li RL, Purssell RA. Cardiovascular toxicity after ingestion of "Herbal Ecstacy." J Emerg Med. 1999; 17:289-91.
23. Zaacks SM, Klein L, Tan CD et al. Hypersensitivity myocarditis associated with ephedra use. Clin Taxicol. 1999; 37:485-9.
24. Vahedi K, Domigo V, Bousser M-G. Ischaemic stroke in a sportsman who consumed ma huang extract and creatine monohydrate for body building. J Neurol Neurosurg Psychiatry. 2000; 68:112-3. Letter.
25. Zhang JS, Tian Z, Lou Z.C. Quality evaluation of twelve species of Chinese ephedra (ma-huang). Acta Pharm Sinica. 1989; 24: 865-71.
26. Lake CR, Quirk RS. CNS stimulants and the look-alike drugs. Psychiatr Clin North Am. 1984; 7:689-701.
27. Pentel P. Toxicity of over-the-counter stimulants. JAMA. 1984; 252:1898-903.
28. Gurley BJ, Wang P, Gardner SF. Ephedrine-type alkaloid content of nutritional supplements containing Ephedra sinica (ma huang) as determined by high performance liquid chromatography. J Pharm Sci. 1998; 87: 1547-53.
29. U.S. House of Representatives, Select Committee on Narcotics Abuse and Control Hearings. Further investigation of look-alike drugs (97th Cong., 1982 Aug 12).
30. Lasagna L. Phenylpropanolamine - a review. New York: Wiley; 1988:239-80.
31. New drug status of OTC combination drug products containing caffeine, phenylpropanolamine, and ephedrine. Fed Reg. 1982; 47:35344-5.
32. Michaelis RC, Holloway FA, Bird DC et al. Interactions between stimulants: effects on DRL performance and lethality in rats. Pharmacol Biochem Behav. 1987; 27:299-306.
33. Walker JS. Phenylpropanolamine potentiates caffeine neurotoxicity in rats. J Pharm Sci. 1989; 78:986-9.
34. Young R, Gabryszuk M, Glennon RA. (-)-Ephedrine and caffeine mutually potentiate one another's amphetamine-like stimulus effects. Pharmacol Biochem Behav. 1998; 61: 169-73.
35. Smith DE. Look-alike drugs and drugs of deception: epidemiological, toxicological, clinical considerations. In: Morgan JP, Kagan DV, Brody JS, eds. Phenylpropanolamine: risks, benefits, and controversies. New York: Praeger; 1985:343-61.
36. Ishigooka J, Yoshida Y, Mitsukuni M. Abuse of "Bron:" a Japanese OTC cough suppressant solution containing methylephedrine, codeine, caffeine and chlorpheniramine. Prog Neuropsychopharmacol Biol Psychiatry. 1991; 15:513-21.
37. Keup W. Use, indications and distribution in different countries of the stimulant and hallucinogenic amphetamine derivatives under consideration by WHO. Drug Alcohol Depend. 1986; 17:169-92.
38. Thiel A, Dressler D. Dyskinesias possibly induced by norpseudoephedrine. J Neurol. 1994; 241:167-9.
39. Huang Y, Wang G, Chen C et al. Fructus aurantii reduced portal pressure in portal hypertensive rats. Life Sci. 1995; 57:2011-20.
40. Calapai G, Firenzuoli F, Saitta A et al. Anti-obesity and cardiovascular toxic effects of Citrus aurantium extracts in the rat: a preliminary report. Fitoterapia. 1999; 70:586-92.
41. Gurley BJ, Gardner SF, White LM et al. Ephedrine pharmacokinetics after the ingestion of nutritional supplements containing Ephedra sinica (ma huang). Ther Drug Monit. 1998; 20:439-45.
42. White LM, Gardner SF, Gurley BJ et al. Pharmacokinetic and cardiovascular effects of ma-huang (Ephedra sinica) in normotensive adults. J Clin Pharmacol. 1997; 37:116-22.
43. National Nutritional Foods Association. Home page. www.nnfa.org/quality/GMPs.html (accessed 1999 Sep 27).
44. Regulations to set standards for the formulation, sale and distribution of dietary supplements containing ephedrine from natural ephedra alkaloids and to restrict the sale and distribution of certain drug products containing ephedrine. Tex Reg. 1999; 24:4564-71.